The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2019 | The benefits of dual-targeting triplebodies
Georg Fey
• 15 Mar 2019
Speaking from the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany, Georg Fey, PhD, of the University of Erlangen Nuremberg, Erlangen and Nuremberg, Germany, explains the benefits of dual-targeting triplebodies.
